Global Type-1 Diabetes Treatment Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Type-1 Diabetes Treatment market size will reach US$ 7522 million by 2031.
Type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Type-1 Diabetes Treatment Industry Forecast” looks at past sales and reviews total world Type-1 Diabetes Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Type-1 Diabetes Treatment sales for 2025 through 2031. With Type-1 Diabetes Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Type-1 Diabetes Treatment industry.
This Insight Report provides a comprehensive analysis of the global Type-1 Diabetes Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Type-1 Diabetes Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Type-1 Diabetes Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Type-1 Diabetes Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Type-1 Diabetes Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Type-1 Diabetes Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Rapid-Acting Insulin
Short-Acting Insulin
Others
Segmentation by Application:
Hospitals & Clinics
Academic & Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astellas Pharma
Merck
Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Boehringer Ingelheim GmbH
Novartis
Pfizer Inc.
Abbott Laboratories
Mannkind Corporation
Braun Melsungen AG
Macrogenics, Inc.
Please note: The report will take approximately 2 business days to prepare and deliver.
Type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Type-1 Diabetes Treatment Industry Forecast” looks at past sales and reviews total world Type-1 Diabetes Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Type-1 Diabetes Treatment sales for 2025 through 2031. With Type-1 Diabetes Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Type-1 Diabetes Treatment industry.
This Insight Report provides a comprehensive analysis of the global Type-1 Diabetes Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Type-1 Diabetes Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Type-1 Diabetes Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Type-1 Diabetes Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Type-1 Diabetes Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Type-1 Diabetes Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Rapid-Acting Insulin
Short-Acting Insulin
Others
Segmentation by Application:
Hospitals & Clinics
Academic & Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astellas Pharma
Merck
Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Boehringer Ingelheim GmbH
Novartis
Pfizer Inc.
Abbott Laboratories
Mannkind Corporation
Braun Melsungen AG
Macrogenics, Inc.
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
114 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
